Cell Viability Assays Global Market Report 2024

The cell viability assays market size has grown rapidly in recent years. It will grow from $1.41 billion in 2023 to $1.56 billion in 2024 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to several factors, including increased investment in cancer research, growth in pharmaceutical research and development (R&D) expenditure, expansion of the biotechnology sector, advancements in cell culture techniques, growing demand for stem cell research, increased need for toxicity testing, utilization of real-time cell analysis systems, and the rise in the number of contract research organizations (CROs).

The cell viability assays market size is expected to see rapid growth in the next few years. It will grow to $2.34 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to several factors, including increasing demand for personalized medicine, a rise in government funding for cell-based research, a growing focus on precision medicine, expansion in stem cell research and applications, the increasing availability of automated cell viability analyzers, a rise in the incidence of infectious diseases, a growing emphasis on improving assay accuracy and sensitivity, increasing awareness about the benefits of cell viability assays, a surge in the development of organ-on-a-chip technologies, and increasing demand for regenerative medicine. Major trends in the forecast period include advancements in high-throughput screening methods, the implementation of AI and machine learning algorithms, the development of real-time monitoring systems, the adoption of automated liquid handling systems, the development of multiplex assays to simultaneously measure cell viability, the adoption of more sustainable and eco-friendly reagents, the development of user-friendly assay kits, advancements in electrochemical assays, the implementation of scalable cell viability assays, and the development of assays compatible with primary cells and stem cells.

The growth of the cell viability assay market is expected to be driven by the increasing adoption of cell-based therapeutics. Cell-based therapeutics involve using living cells for various medical purposes, such as tissue repair, disease treatment, and functional restoration. This trend is supported by advancements in biotechnology, rising investments in regenerative medicine, greater acceptance of cell therapies, and advancements in cell engineering and manufacturing. Cell viability assays play a crucial role in this domain by ensuring the viability, functionality, and safety of therapeutic cells, thereby optimizing treatment outcomes and quality assurance. For example, the American Society of Gene & Cell Therapy reported a rise in trials for non-genetically modified cell therapies in Q1 2023 compared to the previous quarter, indicating the increasing momentum in cell-based therapeutics and its impact on the cell viability assay market.

Leading companies in the cell viability assay market are innovating with advanced cell screening technologies to enhance the efficiency and accuracy of drug discovery processes. These technologies enable high-throughput and precise analysis of cell health and responses, thereby improving experimental conditions and therapeutic development. For instance, Arralyze, a technology company based in Germany, introduced CellShepherd, a state-of-the-art platform for single-cell analysis. Utilizing proprietary nanowell glass arrays, CellShepherd enables real-time monitoring of cell-based assays, offering precise cell dispensing, sterile co-culturing, and imaging capabilities. With AI-driven analysis ensuring accurate cell counting and tracking, CellShepherd meets the growing demand for precise single-cell research across biomedical and life science applications.

In February 2022, BD Biosciences, a US-based medical device company, acquired Cytognos, a biotechnology company headquartered in Spain. This acquisition aims to broaden BD's portfolio in areas such as blood cancer diagnostics, minimal residual disease (MRD) detection, and immune monitoring research. Cytognos specializes in providing cell viability assays and clinical flow cytometry solutions, aligning with BD Biosciences' strategic goals in advancing healthcare technologies.

Major companies operating in the cell viability assays market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Becton, Dickinson, and Company, Agilent Technologies Inc., Lonza Group Ltd., PerkinElmer Inc., Sartorius AG, Charles River Laboratories, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Beckman Coulter Inc., Promega Corporation, Abcam Limited, MP Biomedicals, Cayman Chemical Company, Cell Signaling Technology Inc., Enzo Biochem Inc., Creative Bioarray, Abnova Corporation, Biotium, Canvax, Nexcelom Bioscience LLC, G-Biosciences, AAT Bioquest Inc.

North America was the largest region in the cell viability assays market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell viability assays market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cell viability assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cell viability assays are methods employed to assess the ability of cells, tissues, or organs to maintain or recover a state of survival. These assays are utilized to evaluate optimal growth conditions for cells in culture in response to external stimuli, chemicals, and medicinal treatments.

The main products associated with cell viability assays include consumables and instruments. Consumables are items used either once or replaced regularly in the assay process. They find applications in various fields such as basic research, stem cell research, drug discovery and development, clinical and diagnostic applications, and more. These products are utilized by academic and research institutes, pharmaceutical and biotechnology companies, hospital and diagnostic laboratories, among others.

The cell viability assays market research report is one of a series of new reports that provides cell viability assays market statistics, including the cell viability assays industry global market size, regional shares, competitors with cell viability assays market share, detailed cell viability assays market segments, market trends, and opportunities, and any further data you may need to thrive in the cell viability assays industry. These cell viability assays market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cell viability assays market consists of revenues earned by entities by providing services such as assay development services, assay validation services, cell culture services, and data analysis services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell viability assays market also includes sales of microscopes, imaging systems, incubators, plate readers, and automated liquid handling systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.